Henlius Biotech’s Hetronifly (serplulimab) could soon be authorized for use in EU patients with extensive-stage small cell lung cancer (ES-SCLC) after the European Medicines Agency’s human medicine advisory committee, the CHMP, recommended its approval during its latest monthly meeting.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?